Please login to the form below

Not currently logged in
Email:
Password:

Tradjenta

This page shows the latest Tradjenta news and features for those working in and with pharma, biotech and healthcare.

FDA clears Jardiance combo for type 2 diabetes

FDA clears Jardiance combo for type 2 diabetes

In March they secured FDA approval for Glyxambi, which places empagliflozin alongside the active ingredient in their DPP-4 inhibitor product Tradjenta (linagliptin), ahead of competition from AZ and

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...

Infographics